Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Can Clot-Busting drugs help minor stroke patients? major study aims to find out

NCT ID NCT07322835

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This large study in China will follow 5,400 people with minor ischemic stroke to see if clot-busting drugs or mechanical clot removal (reperfusion therapy) leads to better recovery than standard medications. Participants are treated based on their doctor's choice, and researchers will compare outcomes like disability and bleeding risk at 90 days. The goal is to provide real-world evidence to guide treatment decisions for minor strokes.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
reperfusion therapy (intravenous thrombolysis and/or endovascular intervention)
What this could lead to
If successful, this study could clarify whether clot-busting drugs or mechanical clot removal help people with minor strokes recover better than standard medications alone.
What could go wrong
This is an observational study, not a randomized trial, so results may be less definitive. The study is still recruiting, and outcomes depend on real-world treatment choices, which can vary.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 5,400 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Jan 2026

An estimate. Start dates often move.

Expected to finish

Jun 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Patients with minor ischemic stroke (NIHSS ≤ 5) within 24h from onset

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Age \>18 year 2. Pre-stroke mRS ≤1 3. Diagnosis of ischemic stroke, confirmed by imaging (CT or MRI) 4. Stroke onset or last seen well (LSW) to visit ≤ 24h 5. NIHSS ≤ 5 6. Receive standard medication or IVT (TNK or rtPA) ± EVT, or EVT alone; for IVT beyond standard time window, initiation of treatment must occur within 4.5-24h of last seen well and ASPECTs≥7 or Perfusion lesion-ischemic core mismatch (ischemic core volume \<70mL, mismatch rate \>1.2, mismatch volume \>10mL or mismatch between the presence of an abnormal signal on DWI and no visible signal change on FLAIR) 7. Patients or their eligible surrogates provided informed consent Exclusion Criteria: 1. Pregnant or breastfeeding women 2. Patients who already received reperfusion therapy for the current stroke before arriving at the hospital 3. Participation in another interventional clinical trial that could interfere with the outcomes of this study

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Minor ischemic stroke are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • The First Affiliated Hospital, Sun Yat-Sen University

    Guangzhou, Guangdong, 510080, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.